Pre-made Andecaliximab benchmark antibody ( Whole mAb, anti-MMP9/MMP-9 therapeutic antibody, Anti-CLG4B/GELB/MANDP2 Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Andecaliximab biosimilar, Whole mAb, Anti-MMP9/MMP-9 Antibody: Anti-CLG4B/GELB/MANDP2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Andecaliximab (INN; development code GS-5745) is an experimental humanized monoclonal antibody designed for the treatment of cancer and inflammatory diseases.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-024-1mg	1mg	3090
GMP-Bios-ab-024-10mg	10mg	Inquiry
GMP-Bios-ab-024-100mg	100mg	Inquiry
GMP-Bios-ab-024-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Andecaliximab biosimilar, Whole mAb, Anti-MMP9/MMP-9 Antibody: Anti-CLG4B/GELB/MANDP2 therapeutic antibody
INN Name	Andecaliximab
Target	MMP-9
Format	Whole mAb
Derivation	Chimeric (Mouse/Human)
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-III
Est. Status	Discontinued
100% SI Structure	5th9:HL:IM:JN
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2016
Year Recommended	2017
Companies	Gilead Sciences
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	Chronic obstructive pulmonary disease;Crohn's disease;Cystic fibrosis;Rheumatoid arthritis;Ulcerative colitis;Gastric cancer;Solid tumours;Glioblastoma
Development Tech	na